Información de la revista
Vol. 103. Núm. 8.
Páginas 754 (octubre 2012)
Vol. 103. Núm. 8.
Páginas 754 (octubre 2012)
Letter to the Editor
Acceso a texto completo
Cutaneous Vasculitis
Vasculitis cutáneas
Visitas
18634
G. Saisa,
Autor para correspondencia
gsais@csdm.cat

Corresponding author.
, A. Vidallerb
a Unidad de Dermatología, Hospital de Mataró, C.S. Maresme, Barcelona, Spain
b Servicio de Medicina Interna, C.S.U. Bellvitge, Universitat de Barcelona, Barcelona, Spain
Este artículo ha recibido
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Texto completo
To the Editor:

Having read with great interest the excellent review article by Pulido-Pérez et al.1 on the complex topic of vasculitic syndromes published recently in Actas Dermo-Sifiliográficas, we would like to add the following comments:

  • 1

    The authors cite an article by us in support of the assertion that “any vasculitis of the skin may be accompanied by fever, fatigue, or joint pain” and we feel that this reference is not appropriate.2 Our study analyzed prognostic factors in 160 patients with histologically documented cutaneous leukocytoclastic vasculitis. Using multivariate analysis we found paresthesia, fever, and the absence of painful lesions to be risk factors for systemic involvement. Cryoglobulins, arthralgia, and normal temperature were the risk factors identified for chronic cutaneous disease.

    In our experience, most patients with mixed cryoglobulinemia in Spain also have hepatitis C virus infection. In this group of patients, unless the viral infection is cured, vasculitic skin lesions run a very chronic course and recurrent episodes of palpable purpura may occur over many years, leading to marked hemosiderin deposition in the skin of the lower limbs.

  • 2

    With respect to the treatment of cutaneous vasculitis, the authors report that good results have been obtained with oral colchicine, citing an open, uncontrolled study in 13 patients.3 However, the usefulness of colchicine in the treatment of cutaneous vasculitis has not been demonstrated. To date, the only prospective randomized controlled trial to evaluate the efficacy of colchicine in this setting studied 41 patients with leukocytoclastic vasculitis and failed to demonstrate a significant therapeutic effect attributable to the use of this drug.4

References
[1]
A. Pulido-Pérez, J.A. Avilés-Izquierdo, R. Suárez-Fernández.
Vasculitis Cutáneas.
Actas Dermosifiliogr, 103 (2012), pp. 179-191
[2]
G. Sais, A. Vidaller, A. Jucglà, O. Servitje, E. Condom, J. Peyrí.
Prognostic factors in leukocytoclastic vasculitis: A clinicopathologic study of 160 patients.
Arch Dermatol, 134 (1998), pp. 309-315
[3]
J.P. Callen.
Colchicine is effective in controlling chronic cutaneous leukocytoclastic vasculitis.
J Am Acad Dermatol, 13 (1985), pp. 193-200
[4]
G. Sais, A. Vidaller, A. Jucglà, F. Gallardo, J. Peyrí.
Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial.
Arch Dermatol, 131 (1995), pp. 1399-1402

Please cite this article: Sais G, Vidaller A. Vasculitis cutáneas. Actas Dermosifiliogr.2012;103:754.

Copyright © 2012. Elsevier España, S.L. and AEDV
Descargar PDF
Idiomas
Actas Dermo-Sifiliográficas
Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?